[Click eStock] "Daewoong Pharmaceutical, Expected to Achieve 20% Operating Profit Growth This Year as Well"

Daewoong Pharmaceutical is expected to show an operating profit growth rate in the 20% range this year due to sales growth of high-margin drug items.

On the 6th, Lee Seon-kyung, an analyst at IBK Investment & Securities, stated, "Daewoong Pharmaceutical's core specialty drugs with high margins, Pexuclu (for gastroesophageal reflux disease) and Enblo (for diabetes), are expected to show sales growth of 46% and 565%, respectively, this year," adding, "Despite the sales gap from Forsiga (a diabetes treatment drug), whose co-promotion contract ended last year, profitability is expected to improve as sales volume of these high-profit drugs increases."

The analyst also said, "Botulinum toxin 'Nabota' will continue double-digit growth, and new sales will arise from Gemidapa (a diabetes combination drug) of LG Chem, with which a co-promotion contract has been signed," and forecasted, "Daewoong Pharmaceutical's consolidated sales this year will increase by 5.3% from last year to 1,448.5 billion KRW, and operating profit will rise by 22.8% to 150.6 billion KRW."

Meanwhile, Daewoong Pharmaceutical announced that it recorded sales of 1,222 billion KRW, operating profit of 133.4 billion KRW, and an operating profit margin of 11% last year. In particular, operating profit increased by 26% compared to 2022. According to Daewoong Pharmaceutical, this strong performance was mainly driven by the growth of domestic new drugs Pexuclu, Enblo, and Nabota.

This content was produced with the assistance of AI translation services.